Albarrán, V.; Rosero, D.I.; Chamorro, J.; Pozas, J.; San Román, M.; Barrill, A.M.; AlÃa, V.; Sotoca, P.; Guerrero, P.; Calvo, J.C.;
et al. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. Int. J. Mol. Sci. 2022, 23, 12659.
https://doi.org/10.3390/ijms232012659
AMA Style
Albarrán V, Rosero DI, Chamorro J, Pozas J, San Román M, Barrill AM, AlÃa V, Sotoca P, Guerrero P, Calvo JC,
et al. Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. International Journal of Molecular Sciences. 2022; 23(20):12659.
https://doi.org/10.3390/ijms232012659
Chicago/Turabian Style
Albarrán, VÃctor, Diana Isabel Rosero, Jesús Chamorro, Javier Pozas, MarÃa San Román, Ana MarÃa Barrill, VÃctor AlÃa, Pilar Sotoca, Patricia Guerrero, Juan Carlos Calvo,
and et al. 2022. "Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates" International Journal of Molecular Sciences 23, no. 20: 12659.
https://doi.org/10.3390/ijms232012659
APA Style
Albarrán, V., Rosero, D. I., Chamorro, J., Pozas, J., San Román, M., Barrill, A. M., AlÃa, V., Sotoca, P., Guerrero, P., Calvo, J. C., Orejana, I., Pérez de Aguado, P., & Gajate, P.
(2022). Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates. International Journal of Molecular Sciences, 23(20), 12659.
https://doi.org/10.3390/ijms232012659
